The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
UniQure announced that the U.S. FDA agreed that mid-stage study data could support an accelerated approval filing for its Huntington's disease gene therapy. On June 18, the FDA officially opened a pathway for the accelerated approval filing of the treatment. This development marks a significant regulatory milestone in potentially bringing the therapy to market sooner.